Abstract：Objective To analyze the potential pathogenic genomic imbalance in children with unexplained intellectual disability (ID) and/or developmental delay (DD) and its association with phenotypes, and to investigate the value of array-based comparative genomic hybridization (array-CGH) in clinical molecular genetic diagnosis.Methods The whole genome of 16 children with ID/DD was scanned by the array-CGH for detection of genomic copy number variations (CNVs), and the revealed genomic imbalance was confirmed by multiplex ligation-dependent probe amplification. Results G-band karyotyping of peripheral blood cells showed no abnormalities in the 16 children. The results of the array-CGH revealed that 6 (38%) of the 16 patients had genomic CNVs, and 3 cases of CNVs were normal polymorphic changes; 1 CNV was a microdeletion of 4p16.3, which was the critical region for Wolf-Hirschhorn syndrome, and 1 CNV was a microdeletion of 7q11.23, which was the critical region for Williams-Beuren syndrome. Moreover, a CNV was identified with two duplications at 2q22.2 and 15q21.3 in a boy, which proved to have a clinical significance due to its association with ID, brain DD, unusual facies, cryptorchidism, irregular dentition, etc. Conclusions Array-CGH allows for the etiological diagnosis in some of the children with unexplained ID/DD. As a high-throughput and rapid tool, it has a great clinical significance in the etiological diagnosis of ID/DD.
HE Xi-Yu,CHEN Xiao-Chun,LI Ran et al. Molecular diagnosis of children with unexplained intellectual disability/ developmental delay by array-CGH[J]. CJCP, 2015, 17(5): 459-463.
Jeevanandam L. Perspectives of intellectual disability in Asia: epidemiology, policy, and services for children and adults[J]. Curr Opin Psychiatry, 2009, 22(5): 462-468.
[2]
Kwok HW, Chui EM. A survey on mental health care for adults with intellectual disabilities in Asia[J]. J Intellect Disabil Res, 2008, 52(11): 996-1002.
[3]
Croen LA, Grether JK, Selvin S. The epidemiology of mental retardation of unknown cause[J]. Pediatrics, 2001, 107(6): E86.
[4]
Rauch A, Hoyer J, Guth S, et al. Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation[J]. Am J Med Genet A, 2006, 140(19): 2063-2074.
[5]
Novelli A, Ceccarini C, Bernardini L, et al. High frequency of subtelomeric rearrangements in a cohort of 92 patients with severe mental retardation and dysmorphism[J]. Clin Genet, 2004, 66(1): 30-38.
[6]
Shaffer LG, Bejjani BA. Medical applications of array CGH and the transformation of clinical cytogenetics[J]. Cytogenet Genome Res, 2006, 115(3-4): 303-309.
[7]
Oostlander AE, Meijer GA, Ylstra B. Microarray-based comparative genomic hybridization and its applications in human genetics[J]. Clin Genet, 2004, 66(6): 488-495.
[8]
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders[M].Washington, DC: Alllerican Psychiatric Association, 2000.
[9]
Lee C, Iafrate AJ, Brothman AR. Copy number variations and clinical cytogenetic diagnosis of constitutional disorders[J]. Nat Genet, 2007, 39(7 Suppl): S48-54.
[10]
Hulten MA, Dhanjal S, Pertl B. Rapid and simple prenatal diagnosis of common chromosome disorders: advantages and disadvantages of the molecular methods FISH and QF-PCR[J]. Reproduction, 2003, 126(3): 279-297.
[11]
Shaffer LG, Bejjani BA, Torchia B, et al. The identification of microdeletion syndromes and other chromosome abnormalities: cytogenetic methods of the past,new technologies for the future[J]. Am J Med Genet C Semin Med Genet, 2007, 145C(4): 335-345.
[12]
Dale RC, Grattan-Smith P, Nicholson M, et al. Microdeletions detected using chromosome microarray in children with suspected genetic movement disorders: a single-centre study[J]. Dev Med Child Neurol, 2012, 54(7): 618-623.
[13]
Kurian MA. The clinical utility of chromosomal microarray in childhood neurological disorders[J]. Dev Med Child Neurol, 2012, 54(7): 582-583.
Park SJ, Jung EH, Ryu RS, et al. Clinical implementation of whole-genome array CGH as a first-tier test in 5080 pre and postnatal cases[J]. Mol Cytogenet, 2011, 9(4): 12.
[16]
Hart L, Rauch A, Carr AM, et al. LETM1 haploinsufficiency causes mitochondrial defects in cells from humans with Wolf-Hirschhorn syndrome: implications for dissecting the underlying pathomechanisms in this condition[J]. Dis Model Mech, 2014, 7(5): 535-545.
[17]
Cyr AB, Nimmakayalu M, Lonmuir SQ, et al. A novel 4p16.3 microduplication distal to WHSC1 and WHSC2 characterized by oligonucleotide array with new phenotypic features[J]. Am J Med Genet A, 2011, 155A(9): 2224-2228.
[18]
Hannelie E, Jasper JS, Ruben S, et al. Wolf-Hirschhorn syndrome facial dysmorphic features in a patient with a terminal 4p16.3 deletion telomeric to the WHSCR and WHSCR 2 regions[J]. Eur J Hum Genet, 2009, 17(1): 129-132.
[19]
Hammond P, Hannes F, Suttie M, et al. Fine-grained facial phenotype-genotype analysis in Wolf-Hirschhorn syndrome[J]. Eur J Hum Genet, 2012, 20(1): 33-40.
[20]
Martens MA, Wilson SJ, Reutens DC. Research review: Williams syndrome: a critical review of the cognitive, behavioral, and neuroanatomical phenotype[J]. J Child Psychol Psych, 2008, 49(6): 576-608.
[21]
Lisa E, Aaron P, Sherly P, et al. An atypical deletion of the Williams-Beuren syndrome interval implicates genes associated with defective visuospatial processing and autism[J]. J Med Genet, 2007, 44(2): 136-143.
[22]
Mulatinho MV, de Carvalho Serao CL, Scalco F, et al. Severe intellectual disability, omphalocele, hypospadia and high blood pressure associated to a deletion at 2q22.1q22.3: case report[J]. Mol Cytogenet, 2012, 5(1): 30.
[23]
Lynn M, Shah N, Conroy J, et al. A study of alveolar rhabdomyosarcoma copy number alterations by single nucleotide polymorphism analysis[J]. Appl Immunohistochem Mol Morphol, 2014, 22(3): 213-221.
[24]
Timms AE, Dorschner MO, Wechsler J, et al. Support for the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families[J]. JAMA Psychiatry, 2013, 70(6): 582-590.
[25]
Ahn JW, Mann K, Walsh S, et al. Validation and implementation of array comparative genomic hybridisation as a first line test in place of postnatal karyotyping for genome imbalance[J]. Mol Cytogenet, 2010, 15(3): 9.
[26]
Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies[J]. Am J Hum Genet, 2010, 86(5): 749-764.
[27]
Shoukier M, Klein N, Auber B, et al. Array CGH in patients with developmental delay or intellectual disability: are there phenotypic clues to pathogenic copy number variants?[J]. Clin Genet, 2013, 83(1): 53-65.
